Annual report 2022 – record sales with full focus on growing the core business

STOCKHOLM – March 30th, 2023- ContextVision, a medical technology software company specializing in image processing and image analysis, today presents their Annual Report for 2022.  

The Annual Report gives additional information about the record year, where net sales increased by 20% compared to 2021, and EBITDA ended at 49 MSEK or 42%. 2022 was also a unique year in the company’s history, due to the spin-off of Inify Laboratories AB to the shareholders. Since February 2022, previously split costs are fully allocated to the remaining core business within medical imaging. With solid financials in the core business and a growth plan in place to maintain growth above market, the board of directors is proposing a dividend of 0.30 SEK/share for the financial year 2022. 

Printed copies of the report will be distributed upon request by email: finance@contextvision.se 

For further information, please contact:

Markus Hökerberg (CFO)

tel +46 (0)8 7503550, e-mail markush@contextvision.se

About ContextVision 
ContextVision is a medical technology software company specialized in image analysis and artificial intelligence. As the global market leader within image enhancement, we are a trusted partner to leading manufacturers of ultrasound, X-ray and MRI equipment around the world. 

Our expertise is to develop powerful software products, based on proprietary technology and artificial intelligence for image-based applications. Our cutting-edge technology helps clinicians accurately interpret medical images, a crucial foundation for better diagnosis and treatment. 

The company, established in 1983, is based in Sweden with local representation in the US, Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under the ticker CONTX. 

####

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.